Tag:

Russia

Latest Headlines

Latest Headlines

Gilead's Sovaldi faces renewed advocacy CL pressure, this time for China and Russia

China and Russia have become new targets for compulsory-licensing campaigns as an activist group widens its global challenge to Gilead's expensive Sovaldi (sofosbuvir) hepatitis C drug.

Afghan battlefield clotting agent makes a comeback in Russia

Back in the 1980s, the decade of Russia's failed occupation of Afghanistan, the Soviet military developed a novel way of treating blood clots, with trombovazima. Now, Russia's Biotechnopark in Koltsovo is producing tablets and injectables of the "Afghan drug" for the market.

USTR IP watch list heavy on countries in Asia with China and India noted

Once again, more than half of the countries on the U.S. Trade Representative's Priority Watch List for insufficient intellectual-property protection are in Asia. Four other Asia countries also were named to the Watch List as being of lesser concern.

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1 (Part 2)

FiercePharmaAsia  combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.

South Korea's Green Cross teams with Russia's Nanolek on biologics manufacturing

South Korea's Green Cross said it has signed an agreement with Nanolek, a Russia biopharmaceutical company, to produce its biologics in a three-month-old facility said to be state-of-the-art.

Generic, biosimilar revenues look solid in Asia with many Indian firms eyeing innovation

Various recent reports covering the near-term and long-term outlook for the pharmaceutical industry in Asia paint a positive picture with increased revenues coming from the generics and biosimilars industries along with products as specific as human insulin from China.

UPDATED: Novo investing $750M in manufacturing this year

In a conference call after reporting solid sales and earnings, Novo Nordisk CFO Jesper Brandgaard said the company expects to spend 5 billion Danish kroner ($767 million) this year to boost its capacity for manufacturing biopharmaceuticals and APIs and insulin filling, as well as some for new R&D construction.

Teva continues to whittle down manufacturing network

Teva Pharmaceuticals has cut $650 million in costs this year but needs to more than double that over the next two as it faces generic competition to its workhorse multiple sclerosis drug Copaxone. A big part of that will be to continue revamping its production network, CEO Erez Vigodman says.

Abbott, unfazed by political tensions, closes deal for Russia's Veropharm

Mounting political tensions between Russia and the West may have recently scared Germany's Fresenius out of a partnership in the country. But they won't spook Abbott Laboratories out of its VeroPharm buy, it announced Friday.

Fresenius kills Russian partnership as political tensions escalate

Building political tensions between Russia and the West are making it increasingly difficult for drugmakers in the region, prompting Germany's Fresenius to dump a partnership there. The announcement comes as other drug companies have reported their businesses are under pressure in the area.